Hepatocellular Carcinoma Clinical Trial
Official title:
A Pilot Study of Tremelimumab - A Monoclonal Antibody Against CTLA-4 in Combination With Trans-Arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), or Cryoablation in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Background:
- Tremelimumab is a cancer treatment drug that helps the immune system recognize and destroy
cancer cells. Researchers want to see if it can be used to treat advanced liver cancer. The
drug will be given with one of two types of treatment for liver cancer. The first type,
transarterial catheter chemoembolization (TACE), injects chemotherapy drugs into the tumor
through the main blood vessel that is feeding it. That blood vessel is then closed off to
help keep the drugs in the tumor longer. The second type, radiofrequency ablation (RFA), uses
a heated probe to destroy the tumor tissue. Researchers want to study how safe and effective
these treatments are with the study drug.
Objectives:
- To test the safety and effectiveness of Tremelimumab with TACE or RFA for advanced liver
cancer.
Eligibility:
- Individuals at least 18 years of age who have advanced liver cancer that has not responded
to other treatments.
Background:
Worldwide, hepatocellular carcinoma (HCC) is the fifth most common malignancy with a median
survival of 6-9 months. For patients with advanced disease sorafenib is the only approved
drug and this has limited benefit.
Tremelimumab is a monoclonal antibody against cytotoxic T-lymphocyte-associated protein 4
(CTLA4). Anti-CTLA4 therapy has been shown to enhance anti-tumor immunity by blocking
tumor-induced immune suppression of cytotoxic T cells.
Various tumor ablative procedures and techniques have been shown to result in immunogenic
cell death and induction of a peripheral immune response. Both transarterial catheter
chemoembolization (TACE) and radiofrequency ablation (RFA) have been shown to do this, as
well as cryoablation and external beam radiation.
The underlying hypothesis of this study is that the effect of anti-CTLA4 treatment can be
enhanced by TACE or RFA in patients with advanced hepatocellular carcinoma. We will also
evaluate this in the context of cryoablation and radiation in hepatocellular carcinoma (HCC)
and RFA in cholangiocarcinoma.
Objective:
To assess the safety and feasibility of combining Tremelimumab with trans-arterial catheter
chemoembolization (TACE) radiofrequency ablation (RFA), or cryoablation in patients with
advanced HCC.
Eligibility:
Histologically or cytologically confirmed diagnosis of HCC.
Childs-Pugh A/B7 cirrhosis only is allowed. If patient does not have cirrhosis, this
limitation does not apply.
Barcelona Clinic Liver Cancer (BCLC) Stage B and C patients.
Patients must have disease that is not amenable to potentially curative resection,
radiofrequency ablation, or liver transplantation.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |